On December 7th, Guangzhou Pharmaceutical Group's Guangzhou Pharmaceutical International (Macau) Qingzhou Pharmaceutical Factory in Macau passed the examination of Macao Drug Administration and obtained the good manufacturing practice (GMP) certification of traditional Chinese medicine. It is the first certified Chinese medicine manufacturing enterprise since the implementation of Macao's Law on the Registration of Pharmaceutical Activities of Traditional Chinese Medicine and Chinese Patent Medicines and the inauguration of Macao Drug Administration.

Guangyao Group's Baiyunshan Compound Banlangen Granule (low sugar) was successfully approved for Macao Chinese patent medicine registration certificate, which is the first oral innovative new drug approval issued by the same name since the implementation of Macao's Law on the Registration of Traditional Chinese Medicine and Chinese Patent Medicine and the unveiling of Macao Drug Administration.

Chinese medicine has always been one of the important ways to promote the deep cooperation of Guangdong-Hong Kong-Macao Greater Bay Area industry. In 2020, with the goal of promoting Guangdong-Macao cooperation, helping Macao's moderate and diversified economic development and accelerating the internationalization of Chinese medicine, GPHL set up an international headquarters in Macao, and quickly established a production base of Chinese patent medicines that meets GMP standards. Recently, GPHL obtained the license for manufacturing Chinese traditional medicines, and is gradually promoting Chinese patent medicines made in Macao to the world. Nanfang Daily reported this and interviewed Huang Yin, the post-90s youth of Macao and the exclusive agent of Guangzhou Pharmaceutical Group in Macao.